Aim: This study aimed to investigate the safety of insulin degludec (degludec) in relation to age and risk of hypoglycaemia post hoc in individuals with type 2 diabetes (T2D) (SWITCH 2 trial).
| INTRODUCTION
Type 2 diabetes (T2D) is a chronic, progressive disease that frequently necessitates treatment with basal insulin to maintain adequate glycaemic control. 1, 2 In an ageing population with increasing longevity, the global burden of diabetes in individuals 65 years of age or older is projected to increase from 122.8 million in 2017 to 253.4 million in 2045. 3 Hypoglycaemia, primarily associated with diabetes therapies, particularly insulin, is common in T2D, 4, 5 and increases with age and longer duration of diabetes. 6 Non-severe episodes are associated with increased utilization of healthcare services and loss of work time, [7] [8] [9] as well as impairment of quality of life; prevention of these episodes is therefore important. Severe hypoglycaemia is of even greater concern, as it has been shown to be associated with increased risk of cardiovascular events and mortality. 10, 11 As with non-severe events, severe episodes can increase utilization of healthcare resources, with adverse economic consequences. 12 Delay in intensifying treatment with insulin for many individuals with T2D is common, with fear of hypoglycaemia among patients and healthcare providers an important contributing factor. 13 The problem of clinical inertia may be magnified in the context of older individuals. 14 Treatment delay could place older individuals at greater risk of the microvascular and macrovascular complications of diabetes, as they often have less organ reserve and more comorbid conditions than younger individuals. 15 Basal insulin analogues, now in widespread use, have advantages over human insulin in reducing the risk of hypoglycaemia because of better pharmacokinetic/pharmacodynamic (PK/PD) profiles. 16 The basal insulin analogue insulin degludec (degludec) has a PK/PD profile with an ultra-long duration of action, 17 and these PK/PD properties have been shown to be preserved in elderly individuals. 18 In type 1 diabetes, degludec has a four-times lower PD variability than insulin glargine 100 units/mL (glargine U100) (AUC GIR 0-24h,SS , coefficient of variation, 20% vs 82%). 19 The performance of degludec vs glargine U100 has been studied in a large clinical development programme in which degludec was associated with a lower rate of hypoglycaemia, with rate reductions of 17%-86%, compared with glargine U100. 20 In a dedicated cardiovascular outcomes trial (DEVOTE), a statistically significant 40% lower rate of adjudicated severe hypoglycaemia was observed in individuals using degludec compared with those using glargine U100. 21 Most randomized trials of insulins include very few older individuals, a population that is heterogeneous with respect to prevalence and severity of comorbidity, frailty and overall health. 22 Consequently, little information exists concerning the performance of basal insulin analogues in older individuals with diabetes, particularly with respect to hypoglycaemia. A pre-planned meta-analysis of seven trials comparing degludec and glargine U100 in older patients (≥65 years) indicated that degludec had a 24% lower rate of overall confirmed hypoglycaemia vs glargine U100, and a 36% lower rate of confirmed nocturnal hypoglycaemia. 23 Secondary analysis of the DEVOTE trial, which compared degludec with glargine U100, showed that degludec was associated with a lower rate of hypoglycaemia than glargine U100, regardless of age. 24 A post hoc analysis of data from the SWITCH 2 trial 25 has been utilized in the present report to explore whether older (>65 years) individuals with T2D responded similarly to younger individuals, with respect to the definitions of hypoglycaemia used in the primary analysis and other safety parameters when comparing degludec with glargine U100.
| METHODS
The detailed design of the SWITCH 2 trial and results of the primary analysis have been published. 19 Briefly, SWITCH 2 was a randomized, 3 | RESULTS
| Participants
Among the original cohort, 450 (62.5%) participants were 65 years of age or younger and 270 (37.5%) were above 65 years of age (Table 1) . and older participants, respectively). With respect to any age-related differences in inclusion criteria relevant to the risk of hypoglycaemia, a larger proportion of older participants had been treated with insulin for more than 5 years (52.6% vs 47.6% of older and younger participants, respectively). However, fewer older participants had experienced at least one severe hypoglycaemia event during the previous year (14.4% vs 17.6% of older and younger participants, respectively).
Completion rates were comparable for both younger and older participants, and comparable for both treatments, ranging from 89% to 91%.
| Comparisons between age groups in the pooled population
The cumulative number of hypoglycaemic events, by age group, during the two 16-week maintenance periods is shown in Figure 1 . Older participants tended to experience more severe hypoglycaemic events, although the difference was not statistically significant (RR, Mean fasting plasma glucose was also reduced from baseline in both age groups. However, the magnitude of decrement was greater for older compared with younger participants during both treatment 
| Comparisons by treatment within age group
The observed rate of severe or blood glucose (BG)-confirmed symptomatic hypoglycaemia was lower for degludec compared with glargine U100 in older as well as in younger participants during the maintenance period (younger group, 184 vs 263 events/100 patientyears of exposure [PYE] for degludec and glargine U100, respectively; older group, 188 vs 269 events/100 PYE for degludec and glargine U100, respectively) ( Table 2) , with an estimated 31% and 30% lower rates of severe or BG-confirmed symptomatic hypoglycaemic events with degludec compared with glargine U100, in the younger group 
| Adverse events
Over the entire trial, in the safety analysis set, 307 of 444 (69.2%)
younger patients and 194 of 269 (72.2%) older patients reported adverse events (AEs). The percentage of younger patients reporting AEs was almost identical for degludec and glargine U100 (57.5% and 57.8%, respectively). However, for older patients, a smaller proportion reported AEs with degludec (56.9% vs 66.7% for degludec vs glargine U100, respectively).
Serious AEs by preferred term and system organ class occurring ≥5% in either treatment arm for both age groups are listed in Table S1 .
These were mostly upper respiratory in nature. There were seven fatal events in total: two in patients treated with degludec (none in the younger group; one associated with sudden cardiovascular death and one caused by stroke in the older group) and five in patients treated with glargine U100 (one secondary to acute myocardial infarction and one caused by sepsis in the younger group; two associated with malignancy and one caused by sepsis in the older group).
| DISCUSSION
Results of the randomized, double-blind, crossover trial, SWITCH 2, were examined to assess the effect of age on hypoglycaemia risk, comparing degludec with glargine U100. The SWITCH 2 trial was powered to evaluate the superiority of degludec vs glargine U100 with respect to overall symptomatic hypoglycaemia. During the maintenance period, treatment with degludec was associated with statistically significantly lower rates of severe and symptomatic hypoglycaemic events (BG-confirmed) compared with glargine U100, with a 31% reduction in younger patients (≤65 years) and a 30% reduction in older patients (>65 years). Concerning nocturnal symptomatic hypoglycaemia, the reduction in rates were 43% and 41%, respectively, for these age groups. These treatment differences were comparable between age groups, and this lower rate was similar to the 27% lower rate of overall confirmed hypoglycaemia (estimated rate ratio, degludec:glargine U100, 0.73 [95% CI, 0.56; 0.96]) and the 39% lower rate in nocturnal hypoglycaemia (estimated rate ratio, degludec:glargine U100, 0.61 [95% CI, 0.37; 1.03]) during the maintenance period reported in a pre-planned meta-analysis of seven phase IIIa open-label trials in individuals aged at least 65 years of age, comparing degludec and glargine U100 in T2D. 24 In contrast to the SWITCH 2 trial, the core trials in the meta-analysis were powered to detect differences in HbA1c. Nevertheless, these similarly lower rates across trials with heterogeneous patient populations, ranging from insulin-naïve to basalbolus users, with or without an increased risk of hypoglycaemia at baseline, support the overall benefit of treatment with degludec compared with glargine U100.
The number of severe hypoglycaemic events reported in the present analysis were not statistically different by treatment for either age group, probably because the overall number of events was very low. As this was a treat-to-target trial, as expected, no treatment differences were observed in change in HbA1c from baseline in either the older or the younger participants. Younger individuals required a higher mean insulin dose (U/kg) compared with older individuals throughout the trial, which may have been related to greater insulin resistance, in line with the tendency of a higher body mass index among younger individuals.
Older individuals with T2D are generally at increased risk of, and more vulnerable to, hypoglycaemia than younger individuals, for several reasons, including impaired renal function, 26 reduced ability to recognize and respond to hypoglycaemia, 27 and altered physiological responses to low glucose levels. 28 Symptoms of hypoglycaemia become less intense and their symptom profile changes with increasing age, 29 with symptomatic responses manifesting only at BG levels lower than those in younger individuals, leaving less time to recognize and respond to them. 30, 31 Thus, when hypoglycaemia develops in an older individual with T2D, it might not be identified or reported, which may explain the absence of a significantly higher rate of overall hypoglycaemia in older individuals, as was observed in the present study.
Reduced awareness of hypoglycaemia with advancing age may increase the risk that an event progresses in severity and results in more severe events in the older age group. There was a numerically greater rate of severe hypoglycaemia in older individuals compared with younger individuals (RR, 1.38) in the current trial, although the trend was not statistically significant. Severe hypoglycaemia is generally much more common in real-world populations than in randomized clinical trials. 4, 5, 32 In addition, continuous glucose monitoring has demonstrated that many episodes are unrecognized and under-reported. 33 Furthermore, it has been estimated that only 5% of self-reported severe hypoglycaemia events among individuals with diabetes who are underging pharmacological treatment are captured by traditional healthcare utilization-based surveillance systems, suggesting a substantial underestimate of the true burden. 34 This may be related, at least in part, to the low number of episodes of severe hypoglycaemia in both age groups (15 events in 11/413 younger individuals and 12 events in 11/240 older individuals) ( F I G U R E 2 Hypoglycaemic events for younger (≤65 years) and older (>65 years) individuals, by treatment group Abbreviations: BG, blood glucose; CI, confidence interval. Values are treatment ratios (insulin degludec/insulin glargine U100) for the two 16-week maintenance periods. P-values derived using a Poisson model with logarithm of exposure time (100 years) as offset; estimates adjusted for treatment period, period sequence and dosing time as fixed effects, and subjects as a random effect collected. It would have been valuable to assess whether frail patients were at higher risk of the differing severities of hypoglycaemia. In this study, a larger percentage (57.8%) of individuals in the older age group were male; this may affect the generalizability of results to the older adult population, which tends to have a greater proportion of females.
Significant strengths of the SWITCH 2 trial 25 include the doubleblinded, treat-to-target design. A crossover design allowed participants to serve as their own controls when comparing treatment efficacy. In terms of assessing safety, the studies were powered with hypoglycaemia as the primary endpoint, as opposed to HbA1c, which was used in other trials that were being conducted for regulatory purposes. Furthermore, severe as well as BG-confirmed symptomatic hypoglycaemia events were included, and all severe episodes were confirmed by adjudication. Notwithstanding the high proportion of older males in the trial, both the inclusion criteria for hypoglycaemia risk and the inclusion of older individuals in this study provide valuable insight into a population seen in real-world practice.
To conclude, in patients with T2D, older and younger patients were at similar risk of overall symptomatic hypoglycaemia or nocturnal symptomatic hypoglycaemia, but older patients showed a tendency toward higher risk of severe hypoglycaemia. Treatment with degludec led to similar reductions in HbA1c and a similar adverseevent profile, with a lower risk of hypoglycaemia than treatment with glargine U100, both in older and younger individuals with T2D.
